[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100446733":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":33,"centralContacts":38,"locations":46,"responsibleParty":68,"collaborators":70,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":10,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":99,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Institute of Cancer Research, United Kingdom","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DNA repair gene mutation carriers",null,"* Newly diagnosed with prostate cancer (any Gleason score, any stage, any PSA)\n* Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy\n* Patients on active surveillance, with a PSA doubling time of 6 months or less",[13,14,15],"Other: MRI pelvis or CT imaging under clinical management for Pr Ca","Other: Whole body bone scan imaging","Other: PET-CT imaging",[17,23,29],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"MRI pelvis or CT imaging under clinical management for Pr Ca","Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.",[9],[22],"Magnetic resonance imaging or computerized axial tomography",{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Whole body bone scan imaging","bone scan of the whole body (under clinical diagnosis).",[9],[28],"Bone scintigraphy",{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"PET-CT imaging","Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.",[9],[34],{"name":35,"affiliation":36,"role":37},"Rosalind A Eeles, FRCP FRCR","Institute of Cancer Research and Royal Marsden Hospital","PRINCIPAL_INVESTIGATOR",[39,43],{"name":35,"role":40,"phone":41,"phoneExt":10,"email":42},"CONTACT","+44 208 722 4483","rosalind.eeles@icr.ac.uk",{"name":44,"role":40,"phone":41,"phoneExt":10,"email":45},"Elizabeth K Bancroft, PhD","elizabeth.bancroft@rmh.nhs.uk",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Cancer Genetics Unit, Royal Marsden Hospital","RECRUITING","London","Sutton, Surrey","SM2 5PT","United Kingdom","UK",{"type":56,"coordinates":57},"Point",[58,59],-0.12574,51.50853,{"lat":59,"lon":58},[62,65],{"name":63,"role":40,"phone":64,"phoneExt":10,"email":42},"Rosalind Eeles, MA; PhD; FRCP; FRCR; FMedSci","44 208 661 3642",{"name":44,"role":40,"phone":66,"phoneExt":10,"email":67},"44 207 808 2136","elizabeth.bancroft@icr.ac.uk",{"type":69,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[71,73],{"name":72,"class":6},"Cancer Research UK",{"name":74,"class":75},"National Institute for Health Research, United Kingdom","OTHER_GOV","100446733","the-genpet-study---an-imaging-study-of-fch-pet-ct-in-men-with-prostate-cancer-and-a-dna-repair-gene-mutation-100446733",false,"NCT05097274","The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.","An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation (GENPET)","GENPET","Inclusion Criteria:\n\n* Confirmed pathogenic germline mutation in any of the following genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2 or ATM.\n* Over the age of 18\n* Diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either:\n\n  * At a new diagnosis\n  * Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy\n  * Patients on active surveillance with a PSA doubling time of 6 months or less\n\nExclusion Criteria:\n\n* Diagnosis of other malignancy (excluding basal cell cancer\u002Fsquamous cell cancer of the skin) within five years of diagnosis\n* Known metastatic prostate cancer, both local and distant\n* Patients who have received any oncological treatment within the last six months\n* Patients on any investigational drug treatment\n* Patients on steroids\n* Known history of inflammatory\u002Finfective diseases (e.g. sarcoidosis, tuberculosis, inflammatory bowel disease)\n* Contraindications to having an MRI using the standard MRI checklist (e.g. pacemakers, aneurysm clips, claustrophobia)","MALE","18 Years",{"count":87,"type":88},50,"ESTIMATED","OBSERVATIONAL","The aim of the study is to determine if PET-CT imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and MRI\u002FCT of the abdomen \\& pelvis in detecting the increased incidence of metastasis (nodal\u002Fdistant outside the pelvis) in men with prostatic carcinoma with mutations in any of the following germline DNA repair genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, ATM.",[92,93,94,95,96,97,98],"Prostate Cancer","BRCA Mutation","Mismatch Repair Gene Mutation","ATM Gene Mutation","HOXB13 Germline Mutation","CHEK2 Gene Mutation","PALB2 Gene Mutation",[100,101],"FCH-PET-CT","PSMA-PET-CT","2025-12-08",{"date":104,"type":105},"2025-12-16","ACTUAL",{"date":107,"type":105},"2015-10-15",{"date":109,"type":88},"2032-12-31",{"name":5,"class":6},1]